LEEEF · Leef Brands Inc. · Financials
Substantial doubt about the company's ability to continue as a going concern.
“Such uncertainties related to events and conditions raise substantial doubt about the Company’s ability to continue as a going concern. Management’s plans to address these conditions include the equity financings described in Note 19 and Note 24, which raised aggregate gross proceeds of approximately $14.2 million through July 2026, the continued benefit of vertically integrated biomass supply from Salisbury Canyon Ranch on the Company’s gross margins, and continued discipline over operating costs.”View the 10-Q filed Aug 6, 2026
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Chart any reported metric, KPI or segment over time — the full statement history lives here
| Line Item | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| $34.79M | $28.5M | — | |
| $24.3M | $20.81M | — | |
| $10.48M | $7.68M | — | |
| 30.13% | 26.96% | — | |
| $19.7K | $18.98K | — | |
| $3.12M | $2.4M | — | |
| $231.97K | $339K | $339K | |
| $1.26M | $1.04M | — | |
| $18.07M | $15.67M | — | |
| -$7.59M | -$7.99M | — | |
| -21.82% | -28.02% | — | |
| -$6.33M | -$6.94M | — | |
| $2.37M | $5.16M | — | |
| -$7.52M | -$13.33M | — | |
| -$15.11M | -$21.31M | — | |
| $2.52M | $3.31M | — | |
| -$17.63M | -$24.62M | — | |
| -50.68% | -86.41% | — | |
| -$17.63M | -$24.63M | — | |
| USD/shares | -$0.10 | -$0.17 | — |
| USD/shares | -$0.10 | -$0.17 | — |
| shares | 184.91M | 142.6M | — |
| shares | 184.91M | 142.6M | — |
Debt Profile
Annual debt figures are established from 10-K filings and updated by subsequent 10-Q and 8-K disclosures. Instrument balances are not summed into a company total unless the filing itself reports that total.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
Peer medians compare against the 43 similar-size Drug Manufacturers - Specialty & Generic companies (of 100 listed).